Nomination committee appointed

As per specifications set at Meda’s 2013 annual general meeting, a nomination
committee has been appointed. It consists of:

Karl-Magnus Sjölin, Committee Chairman, Stena Sessan Rederi AB

Bert Åke Eriksson, Meda’s Chairman of the Board, Stena Sessan Rederi AB

Evert Carlsson, Swedbank Robur funds

Anders Oscarsson, AMF funds

Lars Backsell, B&E Participation AB
For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878

Karl-Magnus Sjölin, Chairman of the Nomination Committee ph: 46 31-774 35 35
MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in more than 120 countries worldwide and the company is
represented by its own organizations in over 55 countries. The Meda share is
listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm.
Find out more, visit www.meda.se.

Forward-looking Statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.